Diosgenin Mitigates Streptozotocin Diabetes-induced Vascular Dysfunction of the Rat Aorta: The Involved Mechanisms

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 6, 2015, Pages 584-592

  Roghani Dehkordi, Farshad ^a   Roghani, Mehrdad ^b   Baluchnejadmojarad, Tourandokht ^c  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

aorta; diabetes mellitus; diosgenin; streptozotocin

Indexed keywords

ACETYLCHOLINE; DIOSGENIN; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ISOSORBIDE DINITRATE; PHENYLEPHRINE; POTASSIUM CHLORIDE; ANTIDIABETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR RING; ANIMAL; AORTA; DIABETES MELLITUS, EXPERIMENTAL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; ORGAN CULTURE TECHNIQUE; PHYSIOLOGY; VASODILATATION; WISTAR RAT;

ANIMALS; AORTA; DIABETES MELLITUS, EXPERIMENTAL; DIOSGENIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; MALE; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR; VASODILATION;

EID: 84951151731     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000308     Document Type: Article

References (45)

1. Delbin MA, Trask AJ. The diabetic vasculature: physiological mechanisms of dysfunction and influence of aerobic exercise training in animal models. Life Sci. 2014;102:1-9.
2. Baluchnejadmojarad T, Roghani M, Jalali Nadoushan MR, et al. The sesame lignan sesamin attenuates vascular dysfunction in streptozotocin diabetic rats: involvement of nitric oxide and oxidative stress. Eur J Pharmacol. 2013;698:316-321.
3. Kizub IV, Klymenko KI, Soloviev AI. Protein kinase C in enhanced vascular tone in diabetes mellitus. Int J Cardiol. 2014;174:230-242.
4. Fraga-Silva RA, Costa-Fraga FP, Murca TM, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013;61:1233-1238.
5. Adel H, Taye A, Khalifa MM. Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol. 2014;387:1187-1197.
6. Rahman S, Ismail AA, Rahman AR. Treatment of diabetic vasculopathy with rosiglitazone and ramipril: hype or hope? Int J Diabetes Dev Ctries. 2009;29:110-117.
7. Yin Y, Qi F, Song Z, et al. Ferulic acid combined with astragaloside IV protects against vascular endothelial dysfunction in diabetic rats. Biosci Trends. 2014;8:217-226.
8. Tousoulis D, Papageorgiou N, Androulakis E, et al. Diabetes mellitusassociated vascular impairment: novel circulating biomarkers and therapeutic approaches. J Am Coll Cardiol. 2013;62:667-676.
9. Polovina MM, Potpara TS. Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med. 2014;126:38-53.
10. Romeo G, Frangioni JV, Kazlauskas A. Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunction. FASEB J. 2004;18:725-727.
11. Uemura T, Goto T, Kang MS, et al. Diosgenin, the main aglycon of fenugreek, inhibits LXRalpha activity in HepG2 cells and decreases plasma and hepatic triglycerides in obese diabetic mice. J Nutr. 2011; 141:17-23.
12. Ahmed LA, Obaid AA, Zaki HF, et al. Role of oxidative stress, inflammation, nitric oxide and transforming growth factor-beta in the protective effect of diosgenin in monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol. 2014;740:379-387.
13. Manivannan J, Balamurugan E, Silambarasan T, et al. Diosgenin improves vascular function by increasing aortic eNOS expression, normalize dyslipidemia and ACE activity in chronic renal failure rats. Mol Cell Biochem. 2013;384:113-120.
14. Pari L, Monisha P, Mohamed Jalaludeen A. Beneficial role of diosgenin on oxidative stress in aorta of streptozotocin induced diabetic rats. Eur J Pharmacol. 2012;691:143-150.
15. Dias KL, Correia Nde A, Pereira KK, et al. Mechanisms involved in the vasodilator effect induced by diosgenin in rat superior mesenteric artery. Eur J Pharmacol. 2007;574:172-178.
16. Roghani M, Niknam A, Jalali-Nadoushan MR, et al. Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Res Bull. 2010;82:279-283.
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
18. Bertoluci MC, Ce GV, da Silva AM, et al. Endothelial dysfunction as a predictor of cardiovascular disease in type 1 diabetes. World J Diabetes. 2015;6:679-692.
19. Saravanan G, Ponmurugan P, Deepa MA, et al. Modulatory effects of diosgenin on attenuating the key enzymes activities of carbohydrate metabolism and glycogen content in streptozotocin-induced diabetic rats. Can J Diabetes. 2014;38:409-414.
20. Kalailingam P, Kannaian B, Tamilmani E, et al. Efficacy of natural diosgenin on cardiovascular risk, insulin secretion, and beta cells in streptozotocin (STZ)-induced diabetic rats. Phytomedicine. 2014;21:1154-1161.
21. Uemura T, Hirai S, Mizoguchi N, et al. Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues. Mol Nutr Food Res. 2010;54: 1596-1608.
22. Sato K, Fujita S, Iemitsu M. Acute administration of diosgenin or dioscorea improves hyperglycemia with increases muscular steroidogenesis in STZinduced type 1 diabetic rats. J Steroid Biochem Mol Biol. 2014;143:152-159.
23. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904.
24. Barton M. Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol. 2013;13:226-241.
25. Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J. 2013;34:2436-2443.
26. Singh KK, Shukla PC, Quan A, et al. BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. J Thorac Cardiovasc Surg. 2013;146:949-960. e944.
27. Patel BM, Mehta AA. Aldosterone and angiotensin: role in diabetes and cardiovascular diseases. Eur J Pharmacol. 2012;697:1-12.
28. Umbrello M, Dyson A, Feelisch M, et al. The key role of nitric oxide in hypoxia: hypoxic vasodilation and energy supply-demand matching. Antioxid Redox Signal. 2013;19:1690-1710.
29. Ajay M, Achike FI, Mustafa AM, et al. Effect of quercetin on altered vascular reactivity in aortas isolated from streptozotocin-induced diabetic rats. Diabetes Res Clin Pract. 2006;73:1-7.
30. Baluchnejadmojarad T, Roghani M, Imani A. Protective effect of enalapril on vascular reactivity of the rat aorta. Vascul Pharmacol. 2004;40:301-307.
31. Triggle CR, Ding H. A review of endothelial dysfunction in diabetes: a focus on the contribution of a dysfunctional eNOS. J Am Soc Hypertens. 2010;4:102-115.
32. Kazuyama E, Saito M, Kinoshita Y, et al. Endothelial dysfunction in the early-and late-stage type-2 diabetic Goto-Kakizaki rat aorta. Mol Cell Biochem. 2009;332:95-102.
33. Oyadomari S, Gotoh T, Aoyagi K, et al. Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. Nitric Oxide. 2001;5:252-260.
34. Park K, Li Q, Rask-Madsen C, et al. Serine phosphorylation sites on IRS2 activated by angiotensin II and protein kinase C to induce selective insulin resistance in endothelial cells. Mol Cell Biol. 2013;33:3227-3241.
35. Pacurari M, Kafoury R, Tchounwou PB, et al. The renin-angiotensinaldosterone system in vascular inflammation and remodeling. Int J Inflam. 2014;2014:689360.
36. Crespo MJ, Moreta S, Gonzalez J. Cardiovascular deterioration in STZdiabetic rats: possible role of vascular RAS. Pharmacology. 2003;68:1-8.
37. Choi KW, Park HJ, Jung DH, et al. Inhibition of TNF-alpha-induced adhesion molecule expression by diosgenin in mouse vascular smooth muscle cells via downregulation of the MAPK, Akt and NF-kappaB signaling pathways. Vascul Pharmacol. 2010;53:273-280.
38. Androulakis E, Tousoulis D, Papageorgiou N, et al. Inflammation in hypertension: current therapeutic approaches. Curr Pharm Des. 2011; 17:4121-4131.
39. Liu K, Zhao W, Gao X, et al. Diosgenin ameliorates palmitate-induced endothelial dysfunction and insulin resistance via blocking IKKbeta and IRS-1 pathways. Atherosclerosis. 2012;223:350-358.
40. Roghani M, Vaez Mahdavi MR, Jalali-Nadoushan MR, et al. Chronic administration of daidzein, a soybean isoflavone, improves endothelial dysfunction and attenuates oxidative stress in streptozotocin-induced diabetic rats. Phytother Res. 2013;27:112-117.
41. Hulsmans M, Van Dooren E, Holvoet P. Mitochondrial reactive oxygen species and risk of atherosclerosis. Curr Atheroscler Rep. 2012;14:264-276.
42. Esfandiarei M, Lam JT, Yazdi SA, et al. Diosgenin modulates vascular smooth muscle cell function by regulating cell viability, migration, and calcium homeostasis. J Pharmacol Exp Ther. 2011;336:925-939.
43. Kim DS, Jeon BK, Lee YE, et al. Diosgenin induces apoptosis in HepG2 cells through generation of reactive oxygen species and mitochondrial pathway. Evid Based Complement Alternat Med. 2012;2012:981675.
44. Li Y, Wang X, Cheng S, et al. Diosgenin induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma cells. Oncol Rep. 2015; 33:693-698.
45. Gong G, Qin Y, Huang W, et al. Protective effects of diosgenin in the hyperlipidemic rat model and in human vascular endothelial cells against hydrogen peroxide-induced apoptosis. Chem Biol Interact. 2010;184: 366-375.